Forbes March 27, 2024
William A. Haseltine

This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged by disease, injured by trauma, or worn by time to normal function. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.

In this subseries, we focus specifically on gene therapies. We explore the current treatments and examine the advances poised to transform healthcare. Each article in this collection delves into a different aspect of gene therapy’s role within the larger narrative of Regenerative Medicine. The first six stories will cover gene therapy’s history and primary successes.

The period...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
Why Conflicts Of Interest May Not Be As Bad As You Think (And Besides We All Have Them!)
11 drugs now in shortage
AbbVie tries to reassure investors on Humira biosimilar threat
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

Share This Article